DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Icos
Icos
Icos
IL-10 and ICOS Differentially Regulate T Cell Responses in the Brain During Chronic 2 Toxoplasma Gondii Infection 3
Certain Tadalafil Or Any Salt Solvate Thereof and Products Containing
Bristol-Myers Squibb 2019 Annual Report
Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction in Patients with Diabetes Mellitus
Lilly ICOS' Cialis® (Tadalafil) Reaches $1 Billion Global Sales Milestone
Vanderbilt Univ. V. ICOS Corp
Appeals Court Says Pfizer's Method of Use Patent Invalid
Understanding History, and Not Repeating It. Neuroprotection For
(12) United States Patent (10) Patent No.: US 8,258.268 B2 Wu Et Al
Integrins As Therapeutic Targets: Successes and Cancers
ICOS) Receptor Agonist, Feladilimab, Alone and in Combination with Pembrolizumab: Results from INDUCE-1 Relapsed/Refractory Melanoma Expansion Cohorts
Comirnaty, INN-COVID-19 Mrna Vaccine (Nucleoside-Modified)
Lilly ICOS Celebrates a “Promising” First Year of Cialis® (Tadalafil) in the U.S
Improves Erectile Function in ED Patients with Significant, Multiple Comorbid Conditions
Creating a Global Biopharma Leader
(Cd11b/CD18) Enhances Tumor Response to Radiation by Reducing Myeloid Cell Recruitment
Lifestyle Drug Market Booming
Top View
Crystal Structures of Human Group-VIIA Phospholipase A2 Inhibited by Organophosphorus Nerve Agents Exhibit Non-Aged Complexes Uttamkumar Samanta, Stephen D
Lilly ICOS' Cialis (Tadalafil) Makes Impressive Strides in First Six
ICOS Protects Against Mortality from Acute Lung Injury Through Activation of IL-5 Þ Ilc2s
ICOS Signaling Controls Induction and Maintenance of Collagen
Tadalafil: a Long-Acting PDE5 Inhibitor for the Management of Erectile Dysfunction
Kevin M. Flowers, Ph.D. Partner
Platelet–Neutrophil Interactions As Drivers of Inflammatory and Thrombotic Disease
Pfizer's Viagra Patent and the Promise of Patent Protection in China
The Phosphodiesterase-5 Inhibitor Tadalafil Reduces Myocardial Infarct Size
ICOS-Deficient Patients in and Decreased Memory T Cell
18 Jun 2021 KY1044-CT01: Phase I/II Study of Anti-ICOS Antibody at The
An Antibody Targeting ICOS Increases Intratumoral Cytotoxic to Regulatory T Cell Ratio and Induces Tumor Regression
Lilly ICOS LLC Reports First Quarter 2004 Global Cialis Sales of $108 Million -- Cialis Surpasses Levitra in New and Total U.S
ICOS/ICOSL Upregulation Mediates Inflammatory Response and Endothelial Dysfunction in Type 2 Diabetes Mellitus
Cialis(R) (Tadalafil) Overtakes Viagra to Become Number One Selling Erectile Dysfunction Treatment in France
Is Medicinal Opium Production Afghanistan's Answer?
An Antibody Targeting ICOS Increases Intratumoral Cytotoxic to Regulatory T-Cell Ratio and Induces Tumor Regression a C Richard C.A
38Th Annual J.P. Morgan Healthcare Conference